A systematic review and economic evaluation of statins for the prevention of coronary events

Health Technology Assessment

Volumn 11, Issue 14, 2007, Pages

  Ward, S ^a   Jones, M Lloyd ^a   Pandor, A ^a   Holmes, M ^a   Ara, R ^a   Ryan, A ^a   Yeo, W ^b   Payne, N ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ANTIVITAMIN K; ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; COUMARIN; COUMARIN DERIVATIVE; CREATINE KINASE; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LESCOL XL; NEFAZODONE; PHENYTOIN; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TELITHROMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ABDOMINAL PAIN; AGE DISTRIBUTION; ALOPECIA; AMNESIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTERY OCCLUSION; ARTHRALGIA; ASTHENIA; BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG CARCINOGENICITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; EDEMA; ERYTHEMA MULTIFORME; ETHNIC DIFFERENCE; FATIGUE; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL TOXICITY; GRAPEFRUIT; HAIR DISEASE; HEADACHE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPESTHESIA; HYPOGLYCEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MALAISE; MICTURITION; MUSCLE CRAMP; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA AND VOMITING; NONHUMAN; OBESITY; PANCREATITIS; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TINNITUS; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS; VASCULITIS; VISUAL DISORDER; BAYES THEOREM; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; META ANALYSIS (TOPIC); MORTALITY; QUALITY OF LIFE;

BAYES THEOREM; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; META-ANALYSIS AS TOPIC; QUALITY OF LIFE;

EID: 85044707329     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11140     Document Type: Review

References (406)

1. Petersen S, Peto V, Rayner M. Coronary heart disease statistics. 2004 ed. London: British Heart Foundation; 2004.
2. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-87.
3. Cairns JA. Medical management of unstable angina. Lancet 1995; 346:1464-5.
4. National Statistics. Key health statisticsfrom general practice 1998. London: Office for National Statistics; 2000.
5. British Heart Foundation. British Heart Foundation Statistics Website, 1999. URL: www.heartstats.org. Accessed January 2004.
6. Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
7. Sutcliffe SJ, Fox KF. Wood DA, Sutcliffe A, Stoclk K, Wright M, et al. Incidence of coronary heart disease in a health authority in London: review of a community register. BMJ 2003; 326:20.
8. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Save, JL, et al. Transient ischemic attack - proposal for a new definition. N Engl J Med 2002;347:1713-16.
9. Fisher CM. Transient ischemic attacks. N Engl J Med 2002; 347:1642-3.
10. Johnston SC. Transient ischaemic attack. N Engl J Med 2002; 347:1687-92.
11. Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
12. Stroke Association. TIA fact sheet. London: The Stroke Association; 2004.
13. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003; 163:669-76.
14. Gaziano JM, Hebert PR, Hennekens CH. Cholesterol reduction: weighing the benefits and risks. Ann Intern Med 1996;124:914-18.
15. Bamford J, Sandercock P, Dennis M, Warlow C, Jones L, McPherson K, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. I. Methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg Psychiatry 1988;51:1373-80.
16. Du X, Sourbutts J, Cruickshank K, Summers A, Roberts N, Walton E, et al. A community based stroke register in a high risk area for stroke in north west England. J Epidemiol Community Health 1997; 51:472-8.
17. British Heart Foundation. British Heart Foundation Statistics Website. URL: www.heartstats.org. Accessed 7 January 2004.
18. Wolfe CDA, Rudd AG, Howard R, Coshall C, Stewart J, Lawrence E, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: the South London Stroke Register. J Neurol Neurosurg Psychiatry 2002;72:211-16.
19. Burns P Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ 2003;326:584-8.
20. Golledge J. Lower-limb arterial disease. Lancet 1997; 350:1459-65.
21. Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-6.
22. NHS Centre for Reviews and Dissemination. Cholesterol and coronary heart disease: screening and treatment. Effective Health Care 1998; 4:1-16.
23. Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA, et al. What role for statins? A review and economic model. Health. Technol Assess 1999;3(19).
24. Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess 2000;4(23).
25. National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Males, 2001. DH2 No. 28. London: Office for National Statistics; 2003.
26. Lawlor DA, Ebrahim S, Davey Smith G. Sex matters: secular and geographical trends in sex differences in coronary heart disease mortality. BMJ 2001;323:541-5.
27. Beery TA. Gender bias in the diagnosis and treatment of coronary artery disease. Heart Lung 1995;24:427-35.
28. de Belder M. BCIS audit returns of interventional procedures 2001. London: British Cardiac Interventional Society; 2002.
29. Hackett ML, Duncan J R, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
30. Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990;21:848-53.
31. Lovett J K, Dennis MS, Sandercock PAG, Bamford J, Warlow CP, Rothwell PM. Very early risk of stroke after a first transient ischemic attack. Stroke 2003; 34:e138-40.
32. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284:2901-6.
33. Lichtman JH, Krumholz HM, Wang Y, Radford MJ, Brass LM. Risk and predictors of stroke after myocardial infarction among the elderly Circulation 2002;105:1082-7.
34. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381-6.
35. Hiatt WR. Quality of life assessment in peripheral arterial disease. Atherosclerosis 1997;131:S35-6.
36. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med 1994;331:1130-5.
37. Lukkarinen H, Hentinen M. Assessment of quality of life with the Nottingham Health Profile among patients with coronary heart disease. J Adv Nurs 1997;26:73-84.
38. Roebuck A, Furze G, Thompson DR. Health-related quality of life after myocardial infarction: an interview study. J Adv Nurs 2001; 34:787-94.
39. Department of Health. Heart drug available without a prescription. 12 May 2004. URL: http://www.dh.gov.uk/PublicationsAndStatistics/ PressReleases/PressReleasesNotices/fs/en?CONTENT_ID=4082004&chk= zYiI3. Accessed 20 September 2006.
40. Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular'risk reduction. A review of the evidence ftoin recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
41. Department of Health. Prescription cost analysis: England 2003. http://www.dh.gov.uk/assetRoot/04/08/66/05/04086605.xls. Accessed June 2004.
42. Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004; 329:645.
43. Prescription Pricing Authority. Electronic drug tariff. http://www.ppa.org.uk/edt/December_2004/mindex.htm. Accessed December 2004.
44. Thompson A. Patent expiries - how should they affect prescribing advice? Pharmaceutical Journal 2003;271:587-9.
45. Department of Health. Reimbursement prices for four generic medicines. http://www.dh.gov.uk/assetRoot/04/08/98/51/04089851.pdf. Accessed October 2004.
46. Department of Health. National service framework for coronary heart disease. http://www.dh.gov.uk/assetRoot/04/05/75/26/04057526.pdf. Accessed July 2004.
47. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society Guidelines. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004;18:139-85.
48. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
49. Joint Formulary Committee. British National Formulary. http://www.bnf.org/bnf. Accessed November 2004.
50. National Heart, Lung and Blood Institute. Cholesterol lowering medicines: statins. National Heart, Lung and Blood Institute; 2003. http://www.nhlbi.nih.gov/chd/meds1.htm. Accessed November 2004.
51. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
52. Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004; 30:1-2.
53. Pfizer Limited. Lipitor 10 mg, 20 mg, 40 mg, 80 mg tablets. Electronic Medicines Compendium. http://emc.medicines.org.uk. Accessed August 2004.
54. Novartis Pharmaceuticals UK Ltd. Lescol. Electronic Medicines Compendium. 2005. http://emc.medicines.org.uk. Accessed August 2004.
55. Bristol-Myers Squibb Pharmaceuticals Ltd. Lipostat 10 mg, 20 mg, and 40 mg tablets. Electronic Medicines Compendium. 2005. http://emc.medicines.org.uk. Accessed August 2004.
56. Wan Y. Generic pravastatin available in UK. Drug infozone; 2005. http://www.druginfozone.nhs.uk/record%20viewing/viewrecord.aspx?=537133.
57. AstraZeneca UK Limited. Crestor 10 mg, 20 mg and 40 mg film-coated tablets. Electronic Medicines Compendium. 2005. http://emc.medicines.org.uk. Accessed August 2004.
58. EMEA. Press release: European Medicines Agency Committee for Medicinal Products for Human Use 15-18 November 2004. http://www.emea.eu.int/pdfs/ human/press/pr/15298904en.pdf. Accessed December 2004.
59. Merck Sharp & Dohme Limited. Zocor. Electronic Medicines Compendium. 2005. http://emc.medicines.org.uk. Accessed August 2004.
60. Merck Sharp & Dohme. Simvastatin (Zocor®). The use of statins in the management of patients at increased risk of death or other cardiovascular events from coronary heart disease (CHD). Submission to the National Institute for Clinical Excellence; 2004.
61. Royal Pharmaceutical Society of Great. Britain. Practice gui'dance on: sale of over-the-counter sinivastatin. URL: http://www.rpsgb.org.uk/pdfs/ otcsimvastatinguid.pdf. Accessed August 2004.
62. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract 2003;53:684-9.
63. Bandolier. Statins and the law of unintended consequences. Bandolier 2003;113. URL: http://www.jr2.ox.ac.uk/bandolier/ band113/b113-2.html. Accessed September 2006.
64. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.
65. Davey Smith G. Low blood cholesterol and non-atherosclerotic disease mortality: where do we stand? Eur Heart J 1997;18:6-9.
66. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern. Med 1997; 157:1305-10.
67. Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in, osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
68. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart 2002;88:203-6.
69. Insull W, Troendle A,Silvers A, Dunne CW. Substantial non-compliance to dose and time prescriptions for medications treating hypercholesterolemia. Atherosclerosis 1995;115:S93.
70. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
71. Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109;874-85.
72. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
73. Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
74. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
75. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. 2001; CRD Report No. 3. 2nd ed. York: Centre for Reviews and Dissemination.
76. Windeler J, Lange S. Events per person year - a dubious concept. BMJ 1995;310:454-6.
77. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
78. Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessead September 2000.
79. GraphPad Software. GraphPad QuickCalcs. URL: http://www.graphpad.com/ quickcalcs/index.cfm. Accessed September 2006.
80. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993; 306:1367-73.
81. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-30.
82. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
83. Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
84. Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int 1999;56:S222-6.
85. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
86. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41.
87. Sato S, Kobayashi T, Awata N, Reiber JHC, Nakagawa Y, Hiraoka H, et al. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: two-year follow-up of the prevention of coronary sclerosis study. Current Therapeutic Research, Clinical and Experimental 2001; 62:473-85.
88. Koren MJ, Hunninghake DB, ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-9.
89. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome. Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 2004; 110: 1061-8.
90. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291:1071-80.
91. Lesaffre E, Kocmanova D, Lemos PA, Disco CM, Serruys PW. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003;25:2431-47.
92. Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, et al. FLARE Study Group. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Am J Cardiol 1994;73:50-61D.
93. Riegger G, Abletshauser C, Ludwig M, Schwandt P. Widimsky J, Weidinger G, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherasclerosis 1999;144:263-70.
94. Mehra MR, Uber PA, Vivekananthan K, Solis S, Scott RL, Park MH, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002;40:1609-14.
95. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75:455-9.
96. Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72:1031-7.
97. Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S). Lancet 1994;344:1383-9.
98. Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-4.
99. Teo KK, Burton JR, Buller C, Plante S, Yokoyama S, Montague TJ. SCAT Investigators. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibitiion on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis, Trial (SCAT). Can J Cardiol 1997; 13:591-9.
100. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344:633-8.
101. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994;15:255-69.
102. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
103. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 685-98.
104. Rauscher M. Atorvastatin lowers LDL but not risk of CV events in diabetics with ESRD. Link via http://www.druginfozone.nhs.uk/ Record%20Viewing/viewRecord.aspx?id=540410. Accessed September 2006.
105. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003;114:359-64.
106. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson J DG, Hunt D, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-26.
107. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101:627-34.
108. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. European Heart Journal 1999;20:58-69.
109. Liem AH, Van Boven AJ, Veeger NJGM, Withagen AJ, Robles cle Medina RM, Tijssen JGP, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002;23:1931-7.
110. Serruys PWJC, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
111. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
112. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
113. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995;26:1133-9.
114. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, et al. PREDICT Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J Am Coll Cardiol 1997;30:863-9.
115. Jukema JW, Bruschke AVG, Van Boven JA, Reiber JHC, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528-40.
116. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-54.
117. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7.
118. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect, of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication. in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92:711-12.
119. Tonkin AM, Colquhoun D, Emberson J, Hague W, Keech A, Lane G, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 2000;356:1871-5.
120. Tonkin A, Aylward P Colquhoun D, Glasziou P, Harris P, Hunt D, et al. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995; 76:474-9.
121. MRC/BHF. Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41.
122. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991;68:1436-46.
123. Anon. The Lescol in Severe Atherosclerosis (LiSA) trial. Br J Cardiol 1998;5:1-2.
124. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
125. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51.
126. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43.
127. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
128. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8.
129. Colivicchi F, Guido V, Tubaro M, Ammirati F, Montefoschi N, Varveri A, et al. Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. Am J Cardiol 2002;90:872-4.
130. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della. Sopravvivenza nell'Infarto Miocardico). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 2000;1:810-20.
131. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/ IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142:211-17.
132. Ito H. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). J Atheroscler Thromb 2001;8:33-44.
133. Salonen R, Nyyssonen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J. Cardiol 1995;76:34-9C.
134. Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990;21:848-53.
135. Keech A, Colquhoun D, Baker J, Simes RJ, Bradfield R, Best J, et al. Benefits of long term cholesterol lowering therapy using pravastatin among patients with diabetes in the Lipid Study. Aust N ZJ Med 2000;30:172.
136. Haffner SM, Alexander CM, Cook TJ, Boccuzzi, SJ, Musiiner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7.
137. Reech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired, fasting. glucose. Diabetes Care 2003;26:2713-21.
138. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durringtori PN, et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) inpatients with type 2 diabetes. Diabet Med 2002;19:201-11.
139. O'Rourke B, Barbir M, Mitchell AG, Yacoub MH, Banner NR. Efficacy and safety of fluvastatin therapy for hypercholesterolaemia after heart transplantation. Results of a randomised double blind placebo controlled study. Int J Cardiol 2004; 94:235-40.
140. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
141. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1398-402.
142. Holdaas H, Fellstrom. B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31.
143. Keech AC, Armitage JM, Wallendszus KR, Lawson A, Hauer AJ, Nrish SE, et al. Absence of effects of prolonged sinivastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group. Br J Clin Pharmacol 1996; 42:483-90.
144. Wardle J, Armitage J, Collins R, Wallendszus K, Keech A, Lawson A. Oxford Cholesterol Study Group. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. BMJ 1996; 313:75-8.
145. Ho C. Rosuvastatin: do we need another statin? Issues in Emerging Health Technologies 2001;20:1-4.
146. Benghozi R, Bortolini M, Jia Y, Isaacsohn JL, Troendle AJ, Gonasun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002; 89:231-3.
147. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Current Controlled Trials in Cardiovascular Medicine 2001; 2:205-7.
148. Anon. The statin wars: why AstraZeneca must retreat. Lancet 2003;362:1341.
149. Therapeutics Initiative. Serious adverse event analysis: lipid lowering
150. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281:824-9.
151. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA 2004;292:2647-50.
152. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
153. Hunninghake DB, Koren M, on behalf of the ALLIANCE Investigators. Comparison of clinical outcomes in managed care patients with CHD treated in aggressive lipid lowering programs using atorvastatin versus usual care. The ALLIANCE study. Program and abstracts from the American College of Cardiology 53rd Annual Scientific Session, 7-10 March 2004, New Orleans, LA. Late-Breaking Clinical Trials 1; 2004.
154. Gaist D, Rodriguez LAG, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-9.
155. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40.
156. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26.
157. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalised rhabdomyolysis in patients treated with lipid lowering drugs. JAMA 2004;292:2585-90.
158. Food and Drug Administration. FDA approves new drug for lowering cholesterol. URL: http:/Avww.fda.gov/bbs/topics/ANSWERS/2003/ ANS01247.html. Accessed September 2006.
159. Food and Drug Administration. Crestor (ZD4522, rosuvastatin calcium) tablets. FDA Advisory Committee Meeting Briefing Document NDA 21-366 for use of Crestor. URL: http://www.fda.gov/OHRMS/DOCKETS/ac/03/briefing/ 3968BI_02_A-FDA-Clinical%20Review.pdf#search= %22FDA%20Advisory%20Committee%20Meeting%20Briefing%20Document%20NDA%2021- 366%20%22. Accessed September 2006.
160. Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet 2004; 363:2189-90.
161. AstraZeneca. Statins for the prevention of coronary events: the clinical and cost effectiveness of rosuvastatin. Submission to the National Institute for Clinical Excellence; 2004.
162. Wolfe SM. Author's reply. Lancet 2004;364:1578-9.
163. Olsson GO, Fox JC. Correspondence: should rosuvastatin be withdrawn from the market? Company's reply. Lancet 2004;364:1579-80.
164. Waknine Y. Rosuvastatin label change in EU indicates risk of myopathy. Medscape 2004. http://www.medscape.com/reviewarticle/480577. Accessed June 2004.
165. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-Co-A reductase. Proc Nat Acad Sci USA 1999;96:7797-802.
166. Weverling-Rijnsburger, AWE, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-23.
167. Bandolier. Statins and cancer. URL: http://www.jr2.ox.ac.uk/bandolier/ booth/cardiac/statcanc.html. Accessed 1 December 2004.
168. Gaist D, Jeppesen U, Andersen M, Garcia-Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58:1333-7.
169. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001;56:931-3.
170. Shepherd J, Cobbe SM, Lorimer AR, McKillop JH, Ford I, Packard CJ, et al. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18:1718-24.
171. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen ELEM, Buckle BM, et al. The design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Am J Cardiol 1999;84:1192-7.
172. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88:229-33.
173. Tolmie EP, Lindsay GM, Kerr SM, Brown MR, Ford I, Gaw A. Patients' perspectives on statin therapy for treatment of hypercholesterolaemia: a qualitative study. European Journal of Cardiovascular Nursing 2003;2:141-9.
174. Drummond M, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
175. Eddy DM. Technology assessment: the role of mathematical modeling. In Assessing medical technology. Washington DC: National Academy Press; 1985. pp. 144-54.
176. Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003;327:1264.
177. Marshall T, Rouse A. Resource implications. and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ 2002; 325:197-9.
178. Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000;102:722-7.
179. Caro J, Klittich W, Mc Guire A, Ford I, Norrie J, Petitt D, et al. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315:1577-82.
180. Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992; 8:719-34.
181. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996;312:1443-8.
182. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, Jackson PR. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-32.
183. Pickin DM, Payne JN, Haq IU, McCabe C, Ward S, Jackson PR, et al. Statin therapy/HMG Co-A, reductase treatment in the prevention of coronary heart disease. Trent Institute for Health Services Research Guidance Note for Purchasers; 1996.
184. Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm 1999;56:1726-32.
185. Barry M, Heerey A. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland. Ir Med J 2002; 95:133-5.
186. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United, States of a projected risk model. Atherosclerosis 1998;137:S111-16.
187. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409-14.
188. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 2001;22:751-61.
189. McAlister FA, Teo KK. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs 1997;54:235-52.
190. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting, the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999; 159:593-600.
191. Glasziou PP Eckermann SD,. Mulray SE, Simes RJ, Martin AJ, Kirby AU, et al. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective? Med J Aust 2002; 177:428-34.
192. Riviere M, Wang S, Leclerc C, Fitzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ 1997;156:991-7.
193. Lim SS, Vos T, Peeters A, Liew D, McNeil JJ. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust 2001;175:459-64.
194. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 2001;22:919-25.
195. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PWF, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139:272-81.
196. Stevens RJ, Kotari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (London) 2001;101:671-9.
197. Department of Health. Health Survey for England 1998: cardiovascular disease. http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsStatistics/PublicationsStatisticsArticle/fs/ en?CONTENT_ID=4009101&chk=cb7Po1. Accessed March 2004.
198. Office for National Statistics. Mortality Statistics: cause, England and Wales. London: Office for National Statistics, Stationery Office; http://www.statistics.gov.uk/StatBase/xsdataset.asp?vlnk=5670&more=y. Accessed September 2004. 2001.
199. Department of Health. Reimbursement prices for four generic medicines. http://www.dh.gov.uk/assetRoot/04/08/98/51/04089851.pdf. Accessed October 2004.
200. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442-50.
201. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin dipyridamole. Pharmacoeconomics 1999;16:577-93.
202. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003;21(Suppl 1):43-50.
203. Erens B, Primatesta P. Health Survey for England 1998: cardiovascular disease. London: The Stationery Office; 1999.
204. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9.
205. Serruys P, Unger F, Sousa JE, Jatene A, Bonnier HJRM, SchonbergerJPAM. Comparison of coronary artery bypass surgery and stenting for the treatment of muitivessel disease. Eur Heart J 2001; 344:1117-24.
206. National Institute for Clinical Excellence. Health technology appraisal: review of coronary stents and appraisal of drug-eluting stents. London: NICE; 2003. http://www.nice.org.uk/ page.aspx?o=appraisals.inprogress.drugelutingstents. Accessed October 2004. 2003.
207. Meslop K, Boothroyd DB, Hlatky MA. Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 2003; 145:36-41.
208. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney J M, et al. comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60.
209. Ballantyne CM. Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids. Curr Atheroscler Rep 1999; 1:6-8.
210. Wilson K, Marriott J, Fuller S, Lacey L, Gillen D. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. Pharmacoeconomics 2003; 21:1-11.
211. Lachin JM. Biostatistical methods: the assessment of relative risks. Chichester: John Wiley; 2000.
212. Brindle P, Emberson LF, Walker M, Whincup P. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267.
213. Frolkis JP Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002; 113:625-9.
214. Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, et al. A cost-effectiveness model comparing alternative management strategies for the use of glycoprotein IIb/IIIa antagonists in non-ST-elevation acute coronary syndrome. Report to the National Institute for Clinical Excellence. http://www.nice.org.uk/ Docref.asp?d=32030. London: NICE; 2002. Accessed September 2006.
215. Mant J, Wade D, Winner S. Health care needs assessment: stroke. In: Stevens A, Raftery J, Mant J, Simpson S, editors. Health care needs assessment: the epidemiologically based needs assessment reviews, 2nd ed. Oxford: Radcliffe Medical Press; 2004.
216. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health 2003;57:622-7.
217. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004; 35:1490-7.
218. Bosch JL, Hunink MG. Comparison of the Health Utilities Index Mark 3 (HU13) and the EuroQol EQ-5D in patients treated for intermittent claudication. Qual Life Res 2000;9:591-601.
219. Jonsson B, Johannesson M, Kjekshus J, Olsson AG, PL-dersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17:1001-7.
220. Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ 1997;6:589-601.
221. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-39.
222. Mueck AO, Seeger H. Statins and menopausal health. Journal of the British Menopause Society 2002; 8:141-6.
223. National Institute for Clinical Excellence. Guidance for manufacturers and sponsors. London: NICE; 2001.
224. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004. http://www.nice.org.uk/ page.agpx?o=201973. Accessed October 2004.
225. Dennis MS, Bamford JM, Sandercock PA, Warlow CP. Incidence of transient ischemic attacks in Oxfordshire, England. Stroke 1989;20: 333-9.
226. Yeo WW, Yeo KR. Coronary risk versus cardiovascular risk for treatment decisions in mild hypertension. J Cardiovasc Risk 2002; 9:275-80.
227. British Heart Foundation. http://www.heartstats.org/topic.asp?id=18. Accessed October 2004. Statistics database.
228. Bots. ML, van der Wilk EC, Koudstaal PJ, Hofman A, Grobbee DE. Transient neurological attacks in the general population: prevalence, risk factors and clinical relevance. Stroke 1997;28:768-73.
229. Gray D, Hapton JR. Twenty years' experience of myocardial infarction: the value of a heart attack register. Nottingham Heart Attack Register. Br J Clin Pharmacol 1993;47:292-5.
230. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorenson S, Omblus R. Double blind trial of aspirin in primary prevention of MI in patients with stable chronic angine pectoris. Lancet L992; 340:1421-5.
231. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol. vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) [published erratum appears in Eur Heart J 1996;17:4831. Eur Heart J 1996; 17:76-81.
232. Dargie HJ, Ford I, Fox KM. Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Total Ischaemic Burden European Trial (TIBET). Eur Heart J 1996; 17:104-12.
233. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, Miller E, et al. Effects of treatment on outcome in mildly symptomatic patients with ischaemia during daily life. The Atenolol Silent Ischaemia Study (ASIST). Circulation 1994;90:762-8.
234. Haq IU, Ramsey LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999;81:40-6.
235. Maron DJ. Percutaneous coronary intervention versus medical therapy for coronary heart disease [review]. Curr Atheroscler Rep 2000; 2:290-6.
236. Ridker PM, Cannon CP Morrow D, Rifai N, Rose LM., McCabe CH, et al. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
237. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela Wj, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein and-coronary artery disease. N Engl J Med 2005;352:29-38.
238. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002; 23:1908-21.
239. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990;121:293-8.
240. Curtis L, Netten A. Unit-costs of health and social care 2004. Canterbury: PSSRU;2004.
241. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41.
242. Brazier JE, Deverill M, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3(9).
243. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis related conditions. Osteoporosis Int 2002;13:768-76.
244. Van Exel NJA. Assessment of post-stroke quality of life in cost-effectiveness studies: the usefulness of the Barthel Index and the EuroQol-5D, quality of life research. Qual Life Res 2004; 13:427-33.
245. Tengs TO, Lin TH. A meta-analysis of quality of life estimates for stroke. Pharmacoeconomics 2003; 21:191-200.
246. BARI Investigators. Protocol for the Bypass Angioplasty Revascularization Investigation. Circulation 1991;84:1-27.
247. Goodacre S, Nicholl J, Dixon S, Cross E, Angelina K, Arnold J, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004; 328:254.
248. Bradley CJ, Kroll J, Holmes-Rover M. The health and activities limitation index in patients with acute myocardial infarction. J Clin Epidemiol 2000; 53:55-562.
249. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-60.
250. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee M, Sherwin R, et al. Serum cholesterol and mortality findings for men screened in the multiple risk factor intervention trial. Arch Intern Med 1992; 152:1490-500.
251. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study. BMJ 1996; 313:649-51.
252. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
253. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-4.
254. Davy Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993; 306:1367-73.
255. Carlsson CM, Papcke-Benson K. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging 2002;19:793-805.
256. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141:727-34.
257. Prosser LA. Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132:769-79.
258. Berto P, Munro V, Gaddi A, Negrini C, Hutton J, Mast O. Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy. Clinical Drug Investigation 2000;20:109-21.
259. Huse DM, Russell MW, Miller JD, Kraemer DE, D'Agostino RB, Ellison RC, et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82:1357-63.
260. Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001;8:9-16.
261. Yeo KR, Yeo WW. Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used? Heart 2002;87:423-7.
262. Yeo WW, Yeo KR. Predicting CHD risk in patients with diabetes mellitus. Diabet Med 2001;18:341-4.
263. National Statistics Online. Population Estimates for UK, England and Wales, Scotland and Northern Ireland. http://www.statistics.gov.uk/ statbase/Product.asp?vlnk=601&More=N.
264. Statins - who gets them? http://www.innovate.org.uk/ frameset.asp?Link=WhatsNew
265. Jones AF, Walker J, Jewkes C. Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart 2001; 85:47-43.
266. Durrington PN, Prais H, Bhatnagar D, France M, Crowley V, Khan J, et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. [published erratum appears in Lancet 1999;354:166]. Lancet 1999; 353:278-81.
267. McManus RJ, Mant J, Meulendijks CF. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice. BMJ 2002; 324:459-64.
268. Wierzbicki AS, Reynolds TM, Gill K, Alg S, Crook MA. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary'heart disease. J Cardiovasc Risk 2000; 7:63-71.
269. Sheridan.S, Pignone M, Mulrow C. Framingham-based tools. to calculate the global risk of coronary heart disease. J Gen Intern Med 2003;18:1039-52.
270. Haq IU, Ramsay LE, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM 1999;92:379-85.
271. Empana JP. Ducimetiere P Arveiler D, Ferrieres J, Evans A, Ruidavets JB. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003;24:1903-11.
272. Belsey J. Lipid-lowering in coronary heart disease. 1998;1:1-8. http://www.evidence-based-medicine.co.uk/ebmfiles/Gavel_vol1no1.pdf.
273. Furnham A. Overcoming the obstacles - the outsider's view. Arteriosclerosis 1999;147(Suppl 1): S53-6.
274. Dunbar JJ, Stunkard AJ. Adherence to diet and drug regimens. In: Levy RI, Rifkind BM, Dennis BH, Ernst N, editors. Nutrition, lipids and coronary heart disease: a global view. New York: Raven Press; 1979; pp. 391-417.
275. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. BMJ 2000; 320:705-8.
276. Guidelines Committee. European Society of Hypertension, European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1053.
277. Editorial. OTC statins: a bad decision for public health. Lancet 2004;363:1659.
278. Medicines and Healthcare Products Regulatory Agency (MHRA).The reclassification of simvastatin 10mg (Zocor Heart-Pro) over the counter (OTC). London: MHRA; 2004.
279. Do statins have a role in primary prevention? Therapeutics Letter 2003;48(April-June). http://www.ti.ubc.ca/pages/letter48.htm. Accessed December 2004.
280. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999;21:60-4.
281. Packham C, Pearson J, Robinson J, Gray D. Use of statins in general practices, 1996-8: cross sectional study. BMJ 2000; 320:1583-4.
282. Diaz C, Aristegui R, Hernandez G. Primary prevention in patients with non-insulin dependent diabetes mellitus (NIDDM) and albuminuria: AIDA study ('Atorvastatin In Diabetes with Albuminuria'). Atherosclerosis 1997;134:46.
283. ASPEN Atorvastatin as Prevention of CHD Endpoints in patients with Non-insulin dependent diabetes mellitus. 2005. http://www.incirculation.net/whatswhat. Accessed 2005.
284. Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Armstrong J, et at. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the aurora study. Nephrol Dial Transplant 2003; 18:713.,
285. Von Haehling S, Anker SD. Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart 2005; 91:1-2.
286. Novartis. Lescol® following angioplasty sharply reduces risk of cardiac events in patients with advanced coronary artery disease down to that of patients with early stage disease. Manufacturer's website. 31 March 2003.
287. Nakamura H. The design and background characteristics of the study on the primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels (Japanese Mega Study). Atherosclerosis 2000; 151:136.
288. Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Circulation 2003; 108:2292-7.
289. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). http://www.ctsu.ox.ac.uk/projects/search. Accessed July 2005.
290. Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, et al. SPARCL, Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis 2003; 16:389-95.
291. Stegmayr BG, Nasstrom BG, Brannstrom M, Bucht S, Dimeny E, Gosch J, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. J Am Soc Nephrol 2001;9:161A.
292. Waters DD, Guyton JB, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93:154-8.
293. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80:278-86.
294. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanag S, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002; 39:610-16.
295. Betteridge D, Gibson M. Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. Atheroscler Suppl 2004;5:107, Abstract M.464.
296. Franken A, Wolffenbuttel B, Vincent H. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes. Atheroscler Suppl 2004;5:118, Abstract M.513.
297. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, et al. Effect of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147 705-12.
298. Jukema J, Liem A, Dunselman P, van der Sloot J, Lok D, Zwinderman A. LDL-C/HDL-C ratio in patients with coronary artery disease and low HDL-C: the RADAR study [abstract]. Atheroscler Suppl 2004; 5:125, Abstract M.542.
299. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89:268-75.
300. Schwartz GG, Bolognese MA, Tremblav BP, Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J 2004; 148:H1-9.
301. Paoletti R. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8:383-90.
302. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E, HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003; 92:1287-93.
303. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003;91:33-41.
304. Berne C, Siewert-Delle A. Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects: results of the URANUS study [abstract]. Atheroscler Suppl 2004;5:107, Abstract M.463.
305. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakke HD, Buller H, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292:331-7.
306. Baggio G, De Candia O, Forte PL, Mello F, Andriolli A, Donazzan S, et al. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women. Drugs 1994; 47(Suppl 2):59-63.
307. Ballantyne CM, McKenney J, Trippe BS. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol 2000;86:759-63.
308. Bruckert E, Lievre M, Giral P, Crepaldi G, Masana L, Vrolix M, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol 2004; 12:225-31.
309. Buzzi AP, Pastore M. Argentine multicenter evaluation of fluvastatin in the treatment of patients with hypercholesterolemia. Current Therapeutic Research 1997;58:1013-28.
310. Farnier M. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol 2000;85:53-7.
311. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003;92:794-7.
312. Davidson MH. Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med 1994;96:41-4S.
313. Marcus A. Fluvastatin titrate-to-goal clinical practice study: interim results. Clin Cardiol 1994; 17:IV16-20.
314. Hunninghake DB, Davidson MH, Knapp HR, Schrott HG, Manfreda S and the Fluvastatin Study Group. Extended-release fluvastatin 80 mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40 mg for once daily treatment of primary hypercholesterolaemia. Br J Cardiol 2002;9:469-75.
315. Insull W Jr, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L,. et al. Efficacy and safety of once-daily vs. twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hyprercholesterolemia. Arch Intern Med 1994;154:2449-55.
316. Insull W, Marais AD, Aronson R, Manfreda S. Efficacy and safety of fluvastatin ER 80 mg compared with fluvastatin IR 40 mg in the treatment of primary hypercholesterolaemia. Br J Cardiol 2004; 11:148-55.
317. Isaacsohn JL, LaSalle J, Chao G, Gonasun L. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. Clin Ther 2003;25:904-18.
318. Jacotot B, Banga JD, Pfister P, Mehra M. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group. Br J Clin Pharmacol 1994; 38:257-63.
319. Leitersdorf E, Muratti EN, Eliav O, Peters TK. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995; 76:84-8A.
320. Lye M. Elderly patients with hypercholesterolaemia. results with fluvastatin. Atherosclerosis 1997;130:S29.
321. Olsson AG, Pauciullo P, Soska V, Luley C, Pieters E, Broda G, et al. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther 2001;23:45-61.
322. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipiclaemia (FACT study). Atherosclerosis 2000; 150:429-36.
323. Peters TK, Muratti EN, Mehra M. Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia. Drugs 1994; 47(Suppl 2): 64-72.
324. Teramoto T, Goto Y, Kurokawa K, Nakamura H, Yoshida S, Saito Y, et al. Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients. American Journal of Cardiology 1995;76:33-6A.
325. Tomlinson B, Mak TW, Tsui JY, Woo J, Shek CC, Critchley JA, et al. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia. Am J Cardiol 1995; 76:136-9A.
326. Winkler K. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002;87:5485-90.
327. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111:185-91.
328. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG. ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72.
329. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.
330. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. Am J Cardiol 2001;87:554-9.
331. Assmann G, Huwel D, Schussman K-M, Smilde JG, Kosfing M, Withagen AJAM, et al. Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia. Eur J Intern Med 1999; 10:33-9.
332. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Athyrou W, Kontopoulos AG. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia. Clinical Drug Investigation 1998;16:219-27.
333. Cortellaro M. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study, Thromb Haemost 2002; 88:41-7.
334. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
335. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, doubre-blind trial. Circulation 2003; 107:2409-15.
336. Raggi P, Callister TQ, Davidson M, Welty FK, Bachmann GA, Laskey R, et al. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J 2001; 141:722-6.
337. Bertolami MC, Ramires JAF, Nicolau JC, Novazzi JP, Bodanese LC. Open randomized, comparative study of atorvastatin and simvastatin, after 12 weeks treatment, in patients with hypercholesterolemia alone or with combined hypertriglyceridemia. Revista Brasileira de Medicina 2002;59:577-84.
338. Bertolini S, Bittolo Bon G, Campbell LM, Farnier M, Langan J, Mahla G, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130:191-7.
339. Best JD, Nicholson GC, O'Neal DN, Kotowicz MA, Tebbutt NC, Chan KW, et al. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diabetes Nutr Metab 1996; 9:74-80.
340. Bo M, Nicolello MT, Fiandra U, Merradante G, Piliego T, Fabris F. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin. Nutr Metab Cardiovasc Dis 2001; 11:17-24.
341. Boquist S, Karpe F, Danell-Toverud K, Hamsten A. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. Atherosclerosis 2002; 162:163-70.
342. Branchi A, Fiorenza AM, Torri A, Muzio F, Rovellini A, Berra C, et al. Effects of atorvastatin 10 mg and simvastatin 20 mg on serum triglyceride levels in patients with hypercholesterolemia. Current Therapeutic Research, Clinical and Experimental 2001; 62:408-15.
343. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, et al., CARDS Investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003;167:243-55.
344. Ma P. CAVEAT. a randomised, double-blind, parallel group evaluation of cerivastatin 0.4 mg and 0.8 mg compared to atorvastatin 10 mg and 20 mg once daily in patients with combined (type IIb) dyslipidaemia. Br J Cardiol 2000;7:780-6.
345. Chan DC, Watts GF, Mori TA, Barrett PHR, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002; 32:429-36.
346. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
347. Dalla Nora E, Passaro A, Zamboni PF, Calzoni F, Fellin R, Solini A. Atorvastatin improves metabolic Control and endothelial function in type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest 2003;26:73-8.
348. Dallongeville J, Fruchart JC, Maigret P, Bertolini S, Bon GB, Campbell MM, et al. Double-blind comparison of apolipoprotein and lipoprotein particle lowering effects of atorvastatin and pravastatin monotherapy in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 1998;3:103-10.
349. Dart A. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44.
350. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997;79:1475-81.
351. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther 2000;5:27-32.
352. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39:1020-5.
353. Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, et al. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes Obes Metab 2000;2:355-62.
354. Harris KPG, Wheeler DC, Chong CC. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002;61:1469-74.
355. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 1996;18:853-63.
356. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158:407-16.
357. Hunninghake D, Insull W, Knopp R, Davidson M, Lohrbauer L, Jones P, et al. Comparison of the. efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol 2001; 88:635-9.
358. Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001;17:43-50.
359. Nakamura H, Ohashi Y, Maruhama Y, Ninomiya K, Toyota T, Oikawa S, et al. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79:1248-52.
360. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-5.
361. Jilma B, Joukhadar C, Derhaschnig U, Rassoul F, Richter V, Wolzt M, et al. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia. Clin Sci 2003; 104:189-93.
362. Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001;85:47-51.
363. Kadikoylu G, Yukselen V, Yavasoglu I, Bolaman Z. Hemostatic effects of atorvastatin versus simvastatin. Ann Pharmacother 2003; 37:478-84.
364. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002;89:667-71.
365. Kinlay S,Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002;89:1205-7.
366. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003;143:74-80.
367. Magnani G, Carinci V, Magelli C, Potena L, Reggiani LB, Branzi A. Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant 2000; 19:710-15.
368. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P Oliver MF, Waters D, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711-18.
369. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36:410-16.
370. Muscari A, Bastagli L, Poggiopollini G, Tomassetti V, Massarelli G, Boni P et al. Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovasc Drugs Ther 2001;15:453-8.
371. Nawawi H, Osman NS, Yusoff K, Khalid BAK. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia. Horm. Metab Res 2003;35:479-85.
372. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
373. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-8.
374. Oranje WA, Sels J P, Rondas-Colbers GJ, Lemmens PJ, Wolffenbuttel BH. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 2001;311:91-4.
375. Paiva H, Laaksoj, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003;41:219-22.
376. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002; 51:334-42.
377. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002;16:705-10.
378. Recto CS, Acosta S, Dobs A, Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. Clin Cardiol 2000;23:682-8.
379. Renders L, Mayer-Kadner I, Koch C, Scharffe S, Burkhardt K, Veelken R, et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated transplant recipients. Nephrol Dial Transplant 2004;16:141-6.
380. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Maesano A, Versace A, et al. Effects of atorvastatin treatment on sICAM-1 and plasma nitric oxide levels in hypercholesterolemic subjects. Clin Appl Thromb Hemos 2002;8:257-63.
381. Schrott H, Fereshetian AG, Knopp RH, Bays H, Jones PH, Littlejohn TW 3rd, et al. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. J Cardiovasc Pharmacol Ther 1998;31 19-24.
382. Schuster H, Bergerj, Luft FC. Randomised, double-blind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia. Br J Cardiol 1998; 5:597-602.
383. Sposito AC, Santos RD, Amancio RF, Ramires JA, Chapman MJ, Maranhao RC. Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins. Atherosclerosis 2003;166:311-21.
384. Stein DT Devaraj S, Balis D, Adams-Huet B, Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001; 21:2026-31.
385. Stein E, Strutt KL, Miller E. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2001;159:248.
386. Tan KCB, Chow WS, Tam SCF, Ai VHG, Lam CHL, Lam KSL. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87:563-8.
387. Tanaka A, Yamada N, Saito Y, Kawakami M, Ohashi Y, Akanuma Y. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clin Chim Acta 2001; 312:41-7.
388. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999;82:1390-4.
389. Marz W, Wollschlaeger H, Klein G, Neiss A, Wehling M. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the target tangible trial). Am J Cardiol 1999; 84:7-13.
390. van den Akker J M, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R, et al. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16:238-44.
391. Vansant G, Mertens A, Muls E. The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3. Acta Cardiol 2001;56:149-54.
392. Wang K-Y, Ting C-T. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jpn Heart J 2001;42:725-38.
393. Watts GF, Chan DC, Barrett PHR, O'Neill FH, Thompson GR. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int J Obes Relat Metab Disord 2003;27:862-5.
394. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999; 53:609-11.
395. Wolffenbuttel BHR, Mahla G, Muller D, Pentrup A, Black DM. Efficacy and safety of a new cholesterol, synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Neth J Med 1998;52: 131-7.
396. Wu C-C, Sy R, Tanphaichitr V, Hin ATT, Suyono S, Lee YT. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol - a multinational, multicenter, double-blind study. J Formos Med Assoc 2002; 101:478-87.
397. Colhoun H, Betteridge J, Durrington P, Hitman G, Neil A, Livingstone S, et al. Collaborative Atorvastatin Diabetes Study. CARDS. 2004. URL: www.cardstrial.org. Accessed July 2004.
398. Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998; 81:333-5.
399. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al., for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary svndromes. Phase Z of the A to Z trial. JAMA 2001; 292:1307-16.
400. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357-62.
401. Pedersen TR, Berg K, Cook TJ, Faergerman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156: 2085-92.
402. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-16.
403. Department of Health. NHS reference costs 2003. London: Department of Health.
404. Stewart S, Blue L, Walker A, Morrison C, McMurray JJ. An economic analysis of specialist heart failure nurse management in the UK; can we afford not to implement it? Eur Heart J 2002;23:1369-78.
405. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, Karidis K, Tirologos A, Zobolos S, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 2000;36:2090-5.
406. Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events. http://www.nice.org.uk/pdf/HTAreportvasculardisease.pdf